share_log

Biodexa Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Jun 24 20:50
Summary by Futu AI
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, announced positive results from a Phase 2 clinical trial of eRapa™ for the treatment of Familial Adenomatous Polyposis (FAP). The trial, which was partially funded by a $3 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT), reported a 75% non-progression rate at 12 months and a median decrease in overall polyp burden of 17%. Notably, Cohort 2 showed an 81% non-progression rate and a 29% median decrease in polyp burden. These results were presented by Dr. Carol Burke at the 2024 InSIGHT bi-annual meeting in Barcelona. The Phase 3 study of eRapa in FAP will be supported by a $17 million CPRIT grant. eRapa, a proprietary oral tablet formulation of rapamycin, is designed to improve bioavailability...Show More
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, announced positive results from a Phase 2 clinical trial of eRapa™ for the treatment of Familial Adenomatous Polyposis (FAP). The trial, which was partially funded by a $3 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT), reported a 75% non-progression rate at 12 months and a median decrease in overall polyp burden of 17%. Notably, Cohort 2 showed an 81% non-progression rate and a 29% median decrease in polyp burden. These results were presented by Dr. Carol Burke at the 2024 InSIGHT bi-annual meeting in Barcelona. The Phase 3 study of eRapa in FAP will be supported by a $17 million CPRIT grant. eRapa, a proprietary oral tablet formulation of rapamycin, is designed to improve bioavailability and reduce toxicity. The drug has received Orphan Designation in the US, with plans to seek the same in Europe. Biodexa's CEO, Stephen Stamp, expressed optimism that the Phase 2 results, if confirmed in Phase 3, could delay or eliminate the need for surgical resection in FAP patients. The upcoming Phase 3 registrational study will be a double-blind placebo-controlled trial involving approximately 140 high-risk FAP patients.

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.